Curexa (Curexa -East, LLC), Egg Harbor Township, NJ
Is Curexa (Curexa -East, LLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Curexa (Curexa -East, LLC) hold a New Jersey pharmacy license?
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Texas State Board of Pharmacy also lists nonresident license 34357 for CUREXA, EGG HARBOR TOWNSHIP, NJ, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 2586 for Curexa, Egg Harbor Township, NJ, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5698 for Curexa - East, LLC, Egg Harbor Township, NJ, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054022050 for CUREXA-EAST LLC, EGG HARBOR TOWNSHIP, NJ, status ACTIVE and license 054018557 for EHT PHARMACY LLC (dba CUREXA), EGG HARBOR TOWNSHIP, NJ, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002412 for CUREXA - EAST LLC, EGG HARBOR TOWNSHIP, NJ, status ACTIVE (CURRENT) and license PCN.0004044 for CUREXA - EAST LLC (dba CUREXA), EGG HARBOR TOWNSHIP, NJ, status CLOSED (WITHDRAWN), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0012709 for Curexa- East, LLC (dba Curexa), EGG HARBOR TOWNSHIP, NJ, status Active and license A9-0000991 for Curexa- East, LLC (dba Curexa), EGG HARBOR TOWNSHIP, NJ, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301010978 for Curexa-East, LLC, Egg Harbor Township, NJ, status Active, as of Nov 10, 2026.
Has Curexa (Curexa -East, LLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 13, 2023) for Curexa (Curexa -East, LLC). State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Colorado State Board of Pharmacy’s license dataset also lists 3 actions: “CLS Letter of Admonition” dated Jul 14, 2017, case 2017-1242 on nonresident license OSP 5698, “CLS Stipulation” dated Jul 14, 2017, case 2017-1242 on nonresident license OSP 5698 and “CLS Stipulation” dated Sep 30, 2008, case 2009-48 on nonresident license OSP 5698. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Reprimand” dated Sep 22, 2018, case 2017004086 on nonresident license 054018557 and “Fine” dated Sep 22, 2018, case 2017004086 on nonresident license 054018557.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Curexa -East, LLC; Curexa
- Former names FDA gives
- EHT Pharmacy, LLC
- Location
- Egg Harbor Township, NJ
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Sep 13, 2023
- FDA Data Dashboard inspections
- 4 inspections: 1 OAI, 2 VAI, 1 NAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 6 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Curexa -East, LLC dba Curexa (formerly EHT Pharmacy, LLC), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Sep 13, 2023 | Warning letter | Warning Letter Issued 9/13/2023 | FDA copy (archived) |
| Sep 9, 2022 | Form 483 | 483 Issued 09/09/2022 | FDA copy (archived) |
| Oct 9, 2020 | Form 483 | 483 Issued 10/09/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Curexa - East, LLC, Egg Harbor Township, NJ (FEI number 3011761882), matched to this page by exact name, city and state. It lists 4 inspections: 1 OAI, 2 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 5, 2026 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3011761882 | 1304370 |
| Sep 9, 2022 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011761882 | 1179459 |
| Oct 9, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011761882 | 1131026 |
| Aug 31, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011761882 | 1068498 |
Form 483s FDA has published for this site
- Sep 9, 2022: Form 483 to Curexa - East, LLC, published Dec 7, 2022. fda.gov
- Oct 10, 2020: Form 483 to Curexa - East, LLC, published Dec 22, 2020. fda.gov
- Sep 27, 2018: Form 483 to Curexa - East, LLC, published Apr 30, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 6 numbered observations in all, across 2 inspections ending Oct 9, 2020 to Sep 9, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 29, 2022 to Sep 9, 2022: 3 observations
- Firm on the cover
- Curexa -East, LLC dba Curexa, 3007 Ocean Heights Ave, Egg Harbor Township, NJ 08234 -7749
- FEI number
- 3011761882
- Establishment type on the cover
- Producer of non-sterile drug products
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Non-microbial contamination was observed in your production area.
Specifically,
A. We observed blue powder-like residue in several areas of your facility such as:
i.
On 09/02/2022, we observed blue powder-like residue outside of the dedicated rooms used for production of sildenafil, tadalafil, or vardenafil containing <Redacted B4> products. The blue powder-like residue was observed on wall surfaces and along crevices of the wall-mounted air conditioning unit in the "Nonhazardous Compounding <Redacted B4> " room, which is located adjacent to the <Redacted B4> dedicated rooms. The wall-mounteda air conditioning unit is located above and between the table work surfaces and <Redacted B4> hood <Redacted B4>, and remains on to maintain approximately room temperature. No blue colored <Redacted B4> products are produced in the ''Nonhazardous Compounding <Redacted B4>" room. The last time products containing blue coloring were tableted was 08/11/2022. ...
Observation 2
You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.
Specifically,
A. On 09/07/2022, Technician <Redacted B4> did not use a deactivating or decontaminating agent to clean a <Redacted B4> spatula after it was used in the production of Rx <Redacted B4> : HYDROQUINONE 4%/ TRETINOIN 0.025%/HYDROCORTISONE 1 % NOURISIL", in the hazardous product area. The same <Redacted B4> spatula was subsequently used in the production of Rx <Redacted B4>, "C-TESTOSTERONE 178MG7ML". Similar·ly, a <Redacted B4> stirring rod was used in the production of "METHIMAZOLE (ANIMAL)(STOCK)", lot 09072022@<Redacted B4>, and then it was wiped with a paper towel dampened with <Redacted B4> and placed back into a container holding other utensils for use in further production operations. The <Redacted B4> stirring rod is one of <Redacted B4> stirring rods utilized in production of drug products within biological safety cabinet. Quality Department personnel explained that the cleaning process between different hazardous drug products includes wiping work surfaces and utensils with <Redacted B4> as a deactivating and decontaminating agent. ...
Observation 3
Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
Specifically, on 08/29/2022, we observed naltrexone HCl capsules, lot 0825202226, being produced in the dedicated "Non-Hazardous Compounding <Redacted B4> "room. We observed inconsistent fill heights of the drugs, <Redacted B4> mixture loaded into the individual capsules in the <Redacted B4> capsule machine. Approximately 50 out of <Redacted B4> capsules were filled at a noticeably lower <Redacted B4> fill height than the others.
Inspection Aug 26, 2020 to Oct 9, 2020: 3 observations
- Firm on the cover
- EHT Pharmacy LLC dba Curexa, 3007 Ocean Heights Ave, Egg Harbor Township, NJ 0823 4-7749
- FEI number
- 3011761882
- Establishment type on the cover
- Producer of non-sterile drug products
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Non-microbial contamination was observed in your production area.
Specifically, On 8/26/2020, I observed the tableting room had a fine blue dust/residue coating the walls, ceiling, ceiling vent, blender lid, humidifier, air conditioner and a darker accumulation of the blue dust/residue on the wheels of your stationary blender. This blue colored dust/residue, which is generated during the production of tadalafil and sildenafil, was so pervavsive that it had infiltrated into the other production areas of your facility.
On 09/01/2020, the room was reported to be clean, however the blue dust/residue was observed in the humidifier and as a coating on other surfaces.
The blue dust/residue was observed within your Non-Hazardous and Hazardous Rooms. For example, I observed a blue residue inside the unsealed transfer holes that lead to the Hazardous Room. The products compounded in these rooms do not contain blue coloring.
On 09/03/2020, production of Tadalafil 6mg lot PS l was observed in the tableting area. At the same time, in the Hazardous room a hazardous dermatological drug product <Redacted B4> was being produced.
Your firm uses all rooms to produce drug products. ...
Observation 2
Laboratory analysis of hormone sample determined the strength was below the declared label claim.
Specifically, On 09/01/2020, I observed <Redacted B4> had a failing potency result. The contract testing laboratory notified your furn on 07/14/2020 that the <Redacted B4> test result was 89.6% (Spec: <Redacted B4>). The failing result was confirmed by the contract testing laboratory. The stock drug <Redacted B4> was used in the production of approximately 9 other drug products.
On 09/03/2020, when asked if there was an investigation, the director of regulatory, quality and compliance provided a corrective action document with the date of 07/08/2020 for the failing product. I noted that the date of the corrective action was 6 days before the initial failure was notified (07/14/2020).
The pharmacist-in-charge verified and stated the corrective action had not been conducted for drug produced on 08/12/2020 using the failing <Redacted B4> stock.
[(5) (4) I has a beyond use date of 12/22/2020.
The record <Redacted B4> does not have a weight for the ingredient, <Redacted B4> There was no deviation or investigation into this error. ...
Observation 3
Buildings used in the processing of a drug product are not maintained in a good state of repair.
Specifically, I observed the wall in the Hazardous room and your compounding equipment cleaning area in disrepair.
For example,
A) I observed that the wall between the tablet compounding room and the Hazardous room has unsealed holes where blue residue/dust was observed. I observed the blue residue/dust on the perimeter of the wall (i.e. ceiling, floor and sides).
B) Equipment found drying near a yellow painted wall. The wall was tom, scratched, discolored and had dry wall exposed.
Linked 483s whose text is not shown
- Sep 27, 2018: FDA document 120702: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).
| License | Type as the board gives it | Name on the board record | Location | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 34357 | Non-Resident (Not Located in Texas) | CUREXA | EGG HARBOR TOWNSHIP, NJ | Active | No |
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NRP 2586 | Non Resident Pharmacy | Curexa | Egg Harbor Township, NJ | Active |
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 5698 | OSP | Curexa - East, LLC | Egg Harbor Township, NJ | Active |
- Jul 14, 2017: “CLS Letter of Admonition”, license OSP 5698, case 2017-1242, Curexa - East, LLC, Egg Harbor Township, NJ. Board document
- Jul 14, 2017: “CLS Stipulation”, license OSP 5698, case 2017-1242, Curexa - East, LLC, Egg Harbor Township, NJ. Board document
- Sep 30, 2008: “CLS Stipulation”, license OSP 5698, case 2009-48, Curexa - East, LLC, Egg Harbor Township, NJ. Board document
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054022050 | LICENSED PHARMACY | CUREXA-EAST LLC | EGG HARBOR TOWNSHIP, NJ | ACTIVE |
| 054018557 | LICENSED PHARMACY | EHT PHARMACY LLC (dba CUREXA) | EGG HARBOR TOWNSHIP, NJ | CHANGE OF OWNERSHIP |
- Sep 22, 2018: “Reprimand”, license 054018557, case 2017004086, EHT PHARMACY LLC, EGG HARBOR TOWNSHIP, NJ. Reason given in the record: “due to a sister state discipline in the state of Alabama for compounding and dispensing 10mg of Domperidone for human use, which is not approved by the FDA and having expired medications in active stock.” Board list
- Sep 22, 2018: “Fine”, license 054018557, case 2017004086, EHT PHARMACY LLC, EGG HARBOR TOWNSHIP, NJ. Reason given in the record: “due to a sister state discipline in the state of Alabama for compounding and dispensing 10mg of Domperidone for human use, which is not approved by the FDA and having expired medications in active stock.” Board list
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0002412 | NONRESIDENT PHARMACY | CUREXA - EAST LLC | EGG HARBOR TOWNSHIP, NJ | ACTIVE (CURRENT) |
| PCN.0004044 | NONRESIDENT PHARMACY | CUREXA - EAST LLC (dba CUREXA) | EGG HARBOR TOWNSHIP, NJ | CLOSED (WITHDRAWN) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0012709 | Non Resident Pharmacy | Curexa- East, LLC (dba Curexa) | EGG HARBOR TOWNSHIP, NJ | Active |
| A9-0000991 | Non Resident Pharmacy | Curexa- East, LLC (dba Curexa) | EGG HARBOR TOWNSHIP, NJ | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301010978 | Pharmacy | Curexa-East, LLC | Egg Harbor Township, NJ | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Texas State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Texas State Board of Pharmacy disciplinary records
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.